Cholestyramine use in specific populations: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Cholestyramine}} {{CMG}}; {{AE}} {{SS}} ==Use In Specific Populations== ===Pregnancy=== '''Teratogenic Effects, Pregnancy Category C''' There are no adequate a...")
 
(Redirected page to Cholestyramine)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Cholestyramine]]
{{Cholestyramine}}
{{CMG}}; {{AE}} {{SS}}
 
==Use In Specific Populations==
 
===Pregnancy===
 
'''Teratogenic Effects, Pregnancy Category C'''
 
There are no adequate and well controlled studies in pregnant women. The use of cholestyramine in pregnancy or lactation or by women of childbearing age requires that the potential benefits of drug therapy be weighted against the possible hazards to the mother and child. Cholestyramine is not absorbed systemically, however, it is known to interfere with absorption of fat-soluble vitamins; accordingly, regular prenatal supplementation may not be adequate (see PRECAUTIONS: Drug Interactions).
 
===Nursing Mothers===
 
Caution should be exercised when cholestyramine resin is administered to a nursing mother. The possible lack of proper vitamin absorption described in the “Pregnancy” section may have an effect on nursing infants.
 
===Pediatric Use===
 
Although an optimal dosage schedule has not been established, standard texts6,7 list a usual pediatric dose of 240 mg/kg/day of anhydrous cholestyramine resin in two to three divided doses, normally not to exceed 8 g/day with dose titration based on response and tolerance.
 
In calculating pediatric dosages, 80 mg of anhydrous cholestyramine resin are contained in 110 mg of Prevalite®.
 
The effects of long-term drug administration, as well as its effect in maintaining lowered cholesterol levels in pediatric patients, are unknown. (See also ADVERSE REACTIONS.)<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PREVALITE (CHOLESTYRAMINE) POWDER, FOR SUSPENSION [UPSHER-SMITH LABORATORIES INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dd434ef8-8af3-434c-a0a0-9a0b18459ba0 | publisher =  | date =  | accessdate = 10 February 2014 }}</ref>
 
==References==
 
{{Reflist|2}}
 
{{Lipid modifying agents}}
 
[[Category:Hepatology]]
[[Category:Bile acid sequestrants]]
[[Category:Cardiovasuclar Drugs]]
[[Category:Drugs]]

Latest revision as of 13:53, 21 July 2014

Redirect to: